



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/00, C07K 2/00, 5/00, 7/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/09142</b> <b>(43) International Publication Date:</b> 24 February 2000 (24.02.00)
<b>(21) International Application Number:</b> PCT/US99/15692 <b>(22) International Filing Date:</b> 12 July 1999 (12.07.99) <b>(30) Priority Data:</b> 09/132,352                      11 August 1998 (11.08.98)                      US <b>(71) Applicant:</b> MILKHAUS LABORATORY, INC. [US/US]; Larry Hill Road, Corner of Westfall, R.D. 1 Delanson, Delanson, NY 12053 (US). <b>(72) Inventor:</b> MCMICHAEL, John; Larry Hill Road, Corner of Westfall, R.D. 1 Delanson, Delanson, NY 12053 (US). <b>(74) Agent:</b> SHARP, Jeffrey, S.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).		<b>(81) Designated States:</b> AU, CA, IL, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS  <b>(57) Abstract</b>  Methods are provided of treating the symptoms of neurological disorders including those selected from the group consisting of autism, multiple sclerosis and enuresis by administering to a patient diagnosed with the neurological disorder a composition containing an effective amount of secretin.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

## METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS

### BACKGROUND OF THE INVENTION

5 The present invention relates to methods of treatment of neurological disorders, including those neurological disorders selected from the group consisting of autism, multiple sclerosis, and enuresis (bed-wetting).

Autism is a syndrome of early childhood which is characterized by abnormal social relationships, language disorder, rituals and compulsive phenomena including an insistence on the preservation of sameness and uneven intellectual  
10 development. The syndrome appears to be affected by genetic factors and predominantly affects boys. Causes of the disorder are unclear although individual cases have been associated with the congenital rubella syndrome, cytomegalic inclusion disease, phenylketonuria and the fragile X syndrome.

Treatment of autism has generally been limited to systematic application  
15 of behavior and speech therapy. While therapy with butyrophenones has provided some benefits in limiting the most severe forms of behavior such therapy has not been found to resolve the psychosis. Moreover, research with serotonergic antagonists such as fenflurimine to treat unmanageable behavior remains controversial. Accordingly, there remains a need in the art for new treatments for autism.

20 Multiple sclerosis is a slowly progressing demyelinating disease of the central nervous system which is insidious and characterized by multiple and varied neurological symptoms characterized by remissions and exacerbations. The disease is believed to be immunological in nature but treatment with immuno-suppressive agents is not advised. Instead, treatment with oral prednisone and with dexamethasone has  
25 been common with recent treatment with interferon beta showing potentially promising results. Nevertheless, there remains a desire in the art for new and improved methods for treatment of the symptoms of multiple sclerosis.

Enuresis (bed-wetting) is the involuntary and repeated passage of urine while asleep occurring at an age when voluntary control is generally expected.  
30 Enuresis is familial and tends to occur more often in boys than in girls. Traditional treatments have included bladder exercises, motivational counseling, and treatment with

- 2 -

imipramine. More recently, treatment with enuresis alarms has been preferred but is reported to have only a 70% effectiveness rate among 5 to 15-year olds with a relapse rate of 10 to 15%. Accordingly, there still remains a desire for effective means for treatment of enuresis.

5           Of interest to the present application is secretin which is a polypeptide hormone having 27 amino acid residues which is secreted by endocrine cells of the small intestine. Secretion of the hormone is stimulated by low pH as occurs with dumping of the food bolus from the stomach to the intestine. This low pH stimulates secretin to induce the secretion of pancreatic juice that has a high sodium bicarbonate  
10       concentrations which thus neutralized the HCl of the stomach contents. Secretin is used in diagnostic methods to determine gastric activity and small intestine function but its use has not been taught for therapeutic purposes.

### SUMMARY OF THE INVENTION

15           The present invention is directed to methods for the treatment of neurological disorders and their symptoms. In particular, the invention is directed toward the treatment of neurological disorders and associated symptoms which disorders are selected from the group consisting of autism, multiple sclerosis, and enuresis. Specifically, the invention provides a method of treating the symptoms of  
20       neurological disorders comprising the step of administering to a patient diagnosed with a neurological disorder a composition comprising an effective amount of secretin. The methods of the invention preferably administer secretin at a daily dosage of from about  $10^{-8}$  to  $10^{-3}$  mg and more preferably at a daily dosage of about  $10^{-6}$  to  $10^{-4}$  mg. According to the invention the secretin is preferably administered in the presence of a  
25       pharmaceutically acceptable diluent. The compositions of the invention may be administered by a variety of routes of administration including intravenous, intramuscular, subcutaneous, intrathecal, topical, inhalation and oral, with subcutaneous and sublingual administration being preferred. When administered sublingually, a preferred composition comprises  $4 \times 10^{-6}$  mg secretin per 0.05 ml drop.  
30       The composition is then preferably applied sublingually from once to four times daily.

- 3 -

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides method for the treatment of neurological disorders (and symptoms thereof) selected from the group consisting of autism, multiple sclerosis and enuresis through the administration of effective amounts of secretin. The invention also provides pharmaceutical compositions comprising an effective amount of secretin in combination with a physiologically acceptable carrier for administration to patients.

Provided below are case histories of patients being treated according to the invention which provide evidence of the effectiveness of the treatment methods described herein. The following Examples are intended to illustrate practice of the preferred embodiments of the invention. Numerous additional embodiments and improvements are apparent upon consideration of the following Examples.

**EXAMPLE 1**

According to this example, an eight year old boy with autism who exhibited symptoms of bed wetting, poor verbalization and poor sleep patterns was treated with one sublingual drop of secretin daily ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop). After one day of treatment the subject exhibited elimination of bed wetting, increased verbalization, increased cognition, and was sleeping well. Later, when administration of secretin was terminated wet wetting reoccurred. When secretin administration was resumed bed wetting was again eliminated. The other symptoms exhibited similar behavior where they worsened upon removal of secretin administration but improved upon resumption of secretin therapy.

**EXAMPLE 2**

According to this example, a five year old autistic boy was treated according to the method of Example 1 with one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) daily. After about three days of treatment according to the invention, the patient showed cognitive and motor improvement, could follow a pointing finger and exhibited an improved sleep pattern. The subject also showed an

- 4 -

increased spectrum of desired and tolerated foods, cried with tears for the first time ever, began to use three word sentences, and began to self-correct verbal errors.

### EXAMPLE 3

5           According to this example, a seven year old autistic boy was treated according to the method of Example 1 with one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) daily. With the first week of treatment the subject exhibited improved attitude, better manners, improved playing and appropriate self-entertainment. The subject also exhibited improved tolerance to noise and confusion,  
10 improved eye contact, and improved signing and verbal communication.

### EXAMPLE 4

          According to this example, an 8 year old female with a history of emotional and behavioral problems and diagnosed with attention deficit disorder  
15 (ADD)/attention deficit hyperactivity (ADHD) was treated with secretin at the rate of one drop ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) daily. Within two days she reported, and her mother confirmed, better behavior, decreased irritability and decreased or eliminated "explosiveness." After three weeks of the improved status, the patient discontinued the drops. Within 48 hours after ending secretin therapy, the patient was  
20 more explosive, more irritable and depressed. Resumption of administration of secretin restored the improved condition.

### EXAMPLE 5

          According to this example, a 48 year old male with multiple sclerosis  
25 was treated by sublingual administration of one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) from once to three times daily. The subject reported improved nocturia (having to get up once per night vs. 4 times per night previously), decreased bladder urgency during waking hours, improved mobility, more regular bowel function, complete elimination of muscle spasms that previously had interfered with  
30 sleep and mobility, improved appetite.

- 5 -

**EXAMPLE 6**

According to this example, a five year old male diagnosed with primary enuresis and having a family history of the same was treated by administration of one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) twice daily. After one month of treatment the subject did not wet his bed once.

**EXAMPLE 7**

According to this example, a ten year old female diagnosed with primary enuresis was treated by administration of one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) twice daily. Treatment resulted in no bed-wetting for two full months. Treatment was then discontinued and bed-wetting reoccurred. After resuming treatment no more bed-wetting occurred.

**EXAMPLE 8**

According to this example, an eleven year old male diagnosed with primary enuresis had previously been treated with a bed-wetting alarm and other procedures which had been unsuccessful. The subject was treated by administration of one drop of secretin ( $4 \times 10^{-6}$  ml secretin per 0.05 ml drop) twice daily. Treatment initially resulted in dryness 50% of the time. When treatment was increased to two drops of secretin twice daily, wetting decreased to 10 to 15%.

Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.

- 6 -

**WHAT IS CLAIMED IS:**

1. A method of treating the symptoms of neurological disorders selected from the group consisting of autism, multiple sclerosis and enuresis comprising  
5 the step of administering to a patient diagnosed with said neurological disorder a composition comprising an effective amount of secretin wherein the secretin is administered at a daily dosage of about  $10^{-6}$  to  $10^{-4}$  mg.
2. The method of claim 1 wherein the secretin is administered by  
10 means selected from the group consisting of intravenous, intramuscular, subcutaneous, intrathecal, and sublingual.
3. The method of claim 1 wherein the neurological disorder is  
15 autism.
4. The method of claim 1 wherein the neurological disorder is  
multiple sclerosis.
5. The method of claim 1 wherein the neurological disorder is  
20 enuresis.
6. A pharmaceutical composition in dosage form for administration to a subject comprising an effective amount of secretin for treatment of a neurological disorder selected from the group consisting of autism, multiple sclerosis and enuresis  
25 in combination with a physiologically acceptable carrier wherein the secretin is present at a daily dosage of about  $10^{-6}$  to  $10^{-4}$  mg.



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/15692**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 38/00; C07K 2/00, 5/00, 7/00

US CL :514/12; 530/300, 324.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, BIOSIS, USPATFULL, MEDLINE, EMBASE, EUROPATFULL, IPA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	WO 98/52593 A1 (UNIVERSITY OF MARYLAND BALTIMORE) 26 November 1998, see entire document.	1-6

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
30 AUGUST 1999Date of mailing of the international search report  
22 OCT 1999Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230Authorized officer  
AVIS M. DAVENPORT  
Telephone No. (703) 308-0196JOYCE BRIDGERS  
PARALEGAL SPECIALIST  
CHEMICAL MATRIX